A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

K Yung, W; E Albright, R; Olson, J; Fredericks, R; Fink, K; D Prados, M; Brada, M; Spence, A; J Hohl, R; Shapiro, W; Glantz, M; Greenberg, H; G Selker, R; A Vick, N; Rampling, R; Friedman, H; Phillips, P; Bruner, J; Yue, N; Osoba, D; Zaknoen, S; A Levin, V

doi:10.1054/bjoc.2000.1316

Public

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Shared by NobleBlocks on Aug 16, 2000 • 12:00 AM UTC

Authors:

W. Yung

R. Albright

J. Olson

Abstract

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and sa...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!